Bioengineering / Biyomühendislik
Permanent URI for this collectionhttps://hdl.handle.net/11147/4529
Browse
2 results
Search Results
Now showing 1 - 2 of 2
Article Citation - WoS: 3Citation - Scopus: 4Biopatterning of 3d Cellular Model by Contactless Magnetic Manipulation for Cardiotoxicity Screening(Mary Ann Liebert, Inc, 2023) Önbaş, Rabia; Arslan Yıldız, AhuPatterning cells to create three-dimensional (3D) cell culture models by magnetic manipulation is a promising technique, which is rapid, simple, and cost-effective. This study introduces a new biopatterning approach based on magnetic manipulation of cells with a bioink that consists alginate, cells, and magnetic nanoparticles. Plackett-Burman and Box-Behnken experimental design models were used to optimize bioink formulation where NIH-3T3 cells were utilized as a model cell line. The patterning capability was confirmed by light microscopy through 7 days culture time. Then, biopatterned 3D cardiac structures were formed using H9c2 cardiomyocyte cells. Cellular and extracellular components, F-actin and collagen Type I, and cardiac-specific biomarkers, Troponin T and MYH6, of biopatterned 3D cardiac structures were observed successfully. Moreover, Doxorubicin (DOX)-induced cardiotoxicity was investigated for developed 3D model, and IC50 value was calculated as 8.1 μM for biopatterned 3D cardiac structures, which showed higher resistance against DOX-exposure compared to conventional two-dimensional cell culture. Hereby, developed biopatterning methodology proved to be a simple and rapid approach to fabricate 3D cardiac models, especially for drug screening applications. Copyright 2023, Mary Ann Liebert, Inc., publishers.Conference Object Development of 3d Cardiac Models Via Magnetic Manipulation for Drug Screening Studies(Mary Ann Liebert, 2022) Önbaş, Rabia; Arslan Yıldız, AhuDrug discovery and development process comprise of preclinical and clinical phases that are very intensive, long, and expensive research phases. However, drug candidates can fail in clinical trials. Toxicity is the major reason that leads to about 30% of drug development failures. Recently, the withdrawal rate of drugs from the market was increased to 33.3%from5.1%due to cardiotoxicity. When the drug fails at phase I, the reasons are probably related to 2-dimensional (2D) cell culture studies that do not represent the real tissue physiology; therefore, they provide misdirected data about the efficacy and toxicity of drug.